TP53 and acute myeloid leukemia: TP53 mutation was associated with borderline significantly inferior OS (HR 1.93, 95% CI 0.98–3.78, p = 0.053) and significantly inferior EFS (HR 1.89, 95% CI 0.99–3.59, p = 0.049, respectively) in AML‐MRC‐H.